

Uwe Reuter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6475915/publications.pdf>

Version: 2024-02-01

118
papers

8,822
citations

47004

47
h-index

43886

91
g-index

131
all docs

131
docs citations

131
times ranked

4551
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. <i>Nature Medicine</i> , 2002, 8, 136-142.	30.7	1,083
2	A Controlled Trial of Erenumab for Episodic Migraine. <i>New England Journal of Medicine</i> , 2017, 377, 2123-2132.	27.0	661
3	Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Neurology</i> , The, 2017, 16, 425-434.	10.2	589
4	Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. <i>Lancet</i> , The, 2018, 392, 2280-2287.	13.7	348
5	Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2016, 15, 382-390.	10.2	312
6	European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. <i>Journal of Headache and Pain</i> , 2019, 20, 6.	6.0	260
7	Products of hemolysis in the subarachnoid space inducing spreading ischemia in the cortex and focal necrosis in rats: a model for delayed ischemic neurological deficits after subarachnoid hemorrhage?. <i>Journal of Neurosurgery</i> , 2000, 93, 658-666.	1.6	221
8	Non-invasive vagus nerve stimulation for PREvention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. <i>Cephalalgia</i> , 2016, 36, 534-546.	3.9	219
9	BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. <i>Cephalalgia</i> , 2011, 31, 573-584.	3.9	204
10	Diagnosis and management of migraine in ten steps. <i>Nature Reviews Neurology</i> , 2021, 17, 501-514.	10.1	194
11	Nuclear factor- κ B as a molecular target for migraine therapy. <i>Annals of Neurology</i> , 2002, 51, 507-516.	5.3	167
12	Efficacy and tolerability of lasmiditan, an oral 5-HT _{1F} receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. <i>Lancet Neurology</i> , The, 2012, 11, 405-413.	10.2	164
13	Erenumab in chronic migraine with medication overuse. <i>Neurology</i> , 2019, 92, e2309-e2320.	1.1	163
14	Acute treatment of migraine with the selective 5-HT _{1F} receptor agonist lasmiditan â€“ A randomised proof-of-concept trial. <i>Cephalalgia</i> , 2010, 30, 1170-1178.	3.9	152
15	European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention â€“ 2022 update. <i>Journal of Headache and Pain</i> , 2022, 23, .	6.0	143
16	Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2007, 6, 1054-1062.	10.2	136
17	Clinical and psychopathological definition of the interictal dysphoric disorder of epilepsy. <i>Epilepsia</i> , 2008, 49, 650-656.	5.1	131
18	European headache federation consensus on the definition of resistant and refractory migraine. <i>Journal of Headache and Pain</i> , 2020, 21, 76.	6.0	126

#	ARTICLE	IF	CITATIONS
19	Erenumab (AMG 334) in episodic migraine. <i>Neurology</i> , 2017, 89, 1237-1243.	1.1	120
20	IL-1 β Stimulates COX-2 Dependent PGE2 Synthesis and CGRP Release in Rat Trigeminal Ganglia Cells. <i>PLoS ONE</i> , 2011, 6, e17360.	2.5	115
21	Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. <i>European Journal of Neurology</i> , 2021, 28, 1716-1725.	3.3	112
22	Male and female sex hormones in primary headaches. <i>Journal of Headache and Pain</i> , 2018, 19, 117.	6.0	107
23	Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. <i>Cephalalgia</i> , 2018, 38, 1611-1621.	3.9	104
24	New insights into migraine pathophysiology. <i>Current Opinion in Neurology</i> , 2006, 19, 294-298.	3.6	95
25	TRPV1 in migraine pathophysiology. <i>Trends in Molecular Medicine</i> , 2010, 16, 153-159.	6.7	90
26	Erenumab in chronic migraine. <i>Neurology</i> , 2019, 92, e2250-e2260.	1.1	83
27	Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. <i>Cephalalgia</i> , 2019, 39, 1455-1464.	3.9	79
28	Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. <i>Current Opinion in Neurology</i> , 2017, 30, 272-280.	3.6	78
29	Early onset of efficacy with erenumab in patients with episodic and chronic migraine. <i>Journal of Headache and Pain</i> , 2018, 19, 92.	6.0	78
30	Structural Gray Matter Alterations in Chronic Migraine: Implications for a Progressive Disease?. <i>Headache</i> , 2017, 57, 400-416.	3.9	75
31	Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. <i>Cephalalgia</i> , 2020, 40, 543-553.	3.9	74
32	Noninvasive near Infrared Spectroscopy Monitoring of Regional Cerebral Blood Oxygenation Changes during Peri-Infarct Depolarizations in Focal Cerebral Ischemia in the Rat. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 950-954.	4.3	69
33	Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial. <i>Cephalalgia</i> , 2022, 42, 108-118.	3.9	69
34	Vertebral artery dissections after chiropractic neck manipulation in Germany over three years. <i>Journal of Neurology</i> , 2006, 253, 724-730.	3.6	68
35	Vascular safety of erenumab for migraine prevention. <i>Neurology</i> , 2020, 94, e497-e510.	1.1	66
36	CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. <i>Journal of Headache and Pain</i> , 2021, 22, 128.	6.0	66

#	ARTICLE	IF	CITATIONS
37	Migraine aura: new information on underlying mechanisms. <i>Current Opinion in Neurology</i> , 2004, 17, 289-293.	3.6	64
38	Effects of Chronic Sumatriptan and Zolmitriptan Treatment on 5-HT1 Receptor Expression and Function in Rats. <i>Cephalalgia</i> , 2004, 24, 398-407.	3.9	61
39	Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. <i>Cephalalgia</i> , 2018, 38, 1622-1631.	3.9	59
40	Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study. <i>Frontiers in Neurology</i> , 2020, 11, 417.	2.4	59
41	The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy. <i>Neurotherapeutics</i> , 2018, 15, 324-335.	4.4	57
42	Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 796-804.	1.9	57
43	Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. <i>Journal of Headache and Pain</i> , 2019, 20, 66.	6.0	56
44	Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. <i>Cephalalgia</i> , 2022, 42, 291-301.	3.9	54
45	Monoclonal antibodies for the prevention of migraine. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1307-1317.	3.1	53
46	Circulating endothelial microparticles in female migraineurs with aura. <i>Cephalalgia</i> , 2015, 35, 88-94.	3.9	52
47	Corticosteroids alter CGRP and melatonin release in cluster headache episodes. <i>Cephalalgia</i> , 2015, 35, 317-326.	3.9	51
48	Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. <i>Cephalalgia</i> , 2019, 39, 1798-1808.	3.9	50
49	Triptans Reduce the Inflammatory Response in Bacterial Meningitis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 988-996.	4.3	49
50	Weather sensitivity in migraineurs. <i>Journal of Neurology</i> , 2011, 258, 596-602.	3.6	44
51	Primary trigeminal afferents are the main source for stimulus-induced CGRP release into jugular vein blood and CSF. <i>Cephalalgia</i> , 2012, 32, 659-667.	3.9	44
52	No Microstructural White Matter Alterations in Chronic and Episodic Migraineurs: A Caseâ€“Control Diffusion Tensor Magnetic Resonance Imaging Study. <i>Headache</i> , 2015, 55, 241-251.	3.9	44
53	A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine. <i>Headache</i> , 2018, 58, 48-59.	3.9	43
54	One-year sustained efficacy of erenumab in episodic migraine. <i>Neurology</i> , 2020, 95, e469-e479.	1.1	41

#	ARTICLE	IF	CITATIONS
55	Perivascular nerves contribute to cortical spreading depression-associated hyperemia in rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 274, H1979-H1987.	3.2	40
56	Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. <i>Journal of Headache and Pain</i> , 2021, 22, 39.	6.0	39
57	Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. <i>Cephalalgia</i> , 2022, 42, 326-334.	3.9	39
58	Placebo Adverse Events in Headache Trials: Headache as an Adverse Event of Placebo. <i>Cephalalgia</i> , 2003, 23, 496-503.	3.9	36
59	Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. <i>Cephalalgia</i> , 2021, 41, 294-304.	3.9	34
60	The pharmacological profile and clinical prospects of the oral 5-HT _{1F} receptor agonist lasmiditan in the acute treatment of migraine. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 46-54.	3.5	33
61	Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis. <i>CNS Drugs</i> , 2021, 35, 805-820.	5.9	30
62	5-HT _{1F} Receptor Agonists: A New Treatment Option for Migraine Attacks?. <i>Neurotherapeutics</i> , 2010, 7, 176-182.	4.4	29
63	Two TRPV1 receptor antagonists are effective in two different experimental models of migraine. <i>Journal of Headache and Pain</i> , 2015, 16, 57.	6.0	29
64	The safety and efficacy of the 5-HT _{1F} receptor agonist lasmiditan in the acute treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1409-1415.	1.8	29
65	Valproic Acid Is Effective in Migraine Prophylaxis at Low Serum Levels: A Prospective Open-Label Study. <i>Headache</i> , 2001, 41, 774-778.	3.9	28
66	Effect of Hyperoxia on Neurogenic Plasma Protein Extravasation in the Rat Dura Mater. <i>Headache</i> , 2006, 46, 1545-1551.	3.9	28
67	Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review. <i>Advances in Therapy</i> , 2020, 37, 4765-4796.	2.9	28
68	Glyceroltrinitrate facilitates stimulated CGRP release but not gene expression of CGRP or its receptor components in rat trigeminal ganglia. <i>Neuropeptides</i> , 2009, 43, 483-489.	2.2	25
69	Methylprednisolone blocks interleukin 1 beta induced calcitonin gene related peptide release in trigeminal ganglia cells. <i>Journal of Headache and Pain</i> , 2016, 17, 19.	6.0	25
70	Characteristics and diagnoses of acute headache in pregnant women – a retrospective cross-sectional study. <i>Journal of Headache and Pain</i> , 2017, 18, 114.	6.0	25
71	CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. <i>Current Pain and Headache Reports</i> , 2018, 22, 38.	2.9	25
72	Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. <i>Cephalalgia</i> , 2021, 41, 6-16.	3.9	25

#	ARTICLE	IF	CITATIONS
73	Long-term Efficacy and Safety of Erenumab. <i>Neurology</i> , 2021, 96, .	1.1	25
74	GBD 2016: still no improvement in the burden of migraine. <i>Lancet Neurology, The</i> , 2018, 17, 929-930.	10.2	24
75	Inducible Nitric Oxide Synthase Does Not Mediate Brain Damage after Transient Focal Cerebral Ischemia in Mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 526-539.	4.3	23
76	The influence of weather on migraine – are migraine attacks predictable?. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 22-28.	3.7	22
77	Migraines with and without aura and their response to preventive therapy with topiramate. <i>Cephalalgia</i> , 2010, 30, 543-551.	3.9	21
78	Multiple cerebral infarctions in a patient with Churg-Strauss syndrome. <i>Journal of Neurology</i> , 2010, 257, 678-680.	3.6	18
79	Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. <i>Journal of Headache and Pain</i> , 2022, 23, 38.	6.0	18
80	Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. <i>Cephalalgia</i> , 2019, 39, 608-616.	3.9	17
81	The potential of lasmiditan in migraine. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642096784.	3.5	17
82	Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience. <i>Journal of Headache and Pain</i> , 2022, 23, 40.	6.0	17
83	Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. <i>Current Medical Research and Opinion</i> , 2022, 38, 731-742.	1.9	17
84	Effects of Parecoxib on Plasma Protein Extravasation and c-Fos Expression in the Rat. <i>Headache</i> , 2006, 46, 276-285.	3.9	16
85	Pathophysiology of headache. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 109-114.	4.2	15
86	Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial. <i>Advances in Therapy</i> , 2021, 38, 5465-5483.	2.9	15
87	Two-year efficacy and safety of erenumab in participants with episodic migraine and 2 prior preventive treatment failures: results from the LIBERTY study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 254-262.	1.9	15
88	Anti-CGRP antibodies: a new approach to migraine prevention. <i>Lancet Neurology, The</i> , 2014, 13, 857-859.	10.2	14
89	Gender Differences in 3-Month Outcomes of Erenumab Treatment – Study on Efficacy and Safety of Treatment With Erenumab in Men. <i>Frontiers in Neurology</i> , 2021, 12, 774341.	2.4	14
90	Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2 preventives were not useful: results from the LIBERTY study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 466-472.	1.9	13

#	ARTICLE	IF	CITATIONS
91	Plasma calcitonin gene-related peptide (CGRP) in migraine and endometriosis during the menstrual cycle. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1251-1259.	3.7	13
92	Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(α-receptor) antibodies. <i>Journal of Headache and Pain</i> , 2021, 22, 158.	6.0	13
93	The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response. <i>Headache</i> , 2020, 60, 2026-2040.	3.9	11
94	Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. <i>Journal of Headache and Pain</i> , 2021, 22, 81.	6.0	11
95	A fluorescence-based method to assess plasma protein extravasation in rat dura mater using confocal laser scanning microscopy. <i>Brain Research Protocols</i> , 2003, 12, 77-82.	1.6	10
96	Brain imaging in pregnant women with acute headache. <i>Journal of Neurology</i> , 2018, 265, 1836-1843.	3.6	10
97	Stromal Cell-Derived Factor-1 Alpha Is Decreased in Women With Migraine With Aura. <i>Headache</i> , 2016, 56, 1274-1279.	3.9	9
98	Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary. <i>Journal of Headache and Pain</i> , 2021, 22, 59.	6.0	9
99	Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study. <i>Cephalalgia</i> , 2022, 42, 20-30.	3.9	9
100	Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial. <i>Journal of Headache and Pain</i> , 2021, 22, 26.	6.0	8
101	Timing and durability of response to erenumab in patients with episodic migraine. <i>Headache</i> , 2021, 61, 1553-1561.	3.9	8
102	Multiple system atrophy masking multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 59-61.	1.4	7
103	Cluster headache therapies: pharmacology and mode of action. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 641-654.	3.1	7
104	Determining the Evolution of Headache Among Regular Users of a Daily Electronic Diary via a Smartphone App: Observational Study. <i>JMIR MHealth and UHealth</i> , 2021, 9, e26401.	3.7	7
105	Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. <i>Cephalalgia</i> , 2010, 30, 1290-1295.	3.9	6
106	Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, e1.62-e1.	1.9	6
107	Erenumab Versus Topiramate for the Prevention of Migraine – A Randomised, Double-Blind, Active-Controlled Phase 4 Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
108	Patients™ and Health Care Workers™ Perception of Migraine Images on the Internet: Cross-sectional Survey Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e32707.	4.3	4

#	ARTICLE	IF	CITATIONS
109	Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis. <i>Headache</i> , 2022, 62, 624-633.	3.9	4
110	Erenumab for episodic migraine prophylaxis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 751-757.	2.8	3
111	Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies. <i>Cephalalgia</i> , 2021, 41, 033310242110289.	3.9	3
112	Lasmiditan for acute migraine treatment. <i>Future Neurology</i> , 2013, 8, 631-638.	0.5	2
113	Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine. <i>Expert Opinion on Pharmacotherapy</i> , 0, , 1-11.	1.8	2
114	Study Design and Protocol of a Randomized Controlled Trial of the Efficacy of a Smartphone-Based Therapy of Migraine (SMARTGEM). <i>Frontiers in Neurology</i> , 0, 13, .	2.4	2
115	Maintenance of Elective Patient Care at Berlin University Children's Hospital During the COVID-19 Pandemic. <i>Frontiers in Pediatrics</i> , 2021, 9, 694963.	1.9	1
116	Assessment of the efficacy of erenumab during the open-label treatment (13-24 weeks) of subjects with episodic migraine who failed 4 prior preventive treatments: results of the LIBERTY study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A31.1-A31.	1.9	0
117	Galcanezumab CONQUERs migraine prevention. <i>Lancet Neurology</i> , The, 2020, 19, 798-799.	10.2	0
118	Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study. <i>European Neurological Review</i> , 2019, 14, 68.	0.5	0